Laryngeal squamous cell carcinoma · line 1 · Pembrolizumab + 5-FU + platinum (HNSCC R/M, 1L; PD-L1 CPS ≥1)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-PEMBRO-CHEMO-HNSCC-1L |
| ID | IND-LARYNGEAL-RM-1L-PEMBRO-CHEMO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-LARYNGEAL |
| Sources | SRC-KEYNOTE-048-BURTNESS-2019 SRC-NCCN-HNSCC-2025 |
Notes
STUB pending Clinical Co-Lead sign-off (CHARTER §6.1). Mirrors IND-HNSCC-RM-1L-PEMBRO-CHEMO field-for-field (same KEYNOTE-048 framework; laryngeal is a HNSCC subsite). Reuses REG-PEMBRO-CHEMO-HNSCC-1L and DRUG-PEMBROLIZUMAB / DRUG-CISPLATIN / DRUG-CARBOPLATIN / DRUG-5-FLUOROURACIL unchanged — no new Regimen or Drug authored for this pathway. RF-HNSCC-INFECTION-SCREENING / RF-HNSCC-ORGAN-DYSFUNCTION reused by reference (their relevant_diseases field still lists DIS-HNSCC only — not modified, per the hard rule against editing existing files).
Used By
Algorithms
ALGO-LARYNGEAL-1L- ALGO-LARYNGEAL-1L